News
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide ... demonstrating a 14% reduction in risk of major ...
Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback